Saturday, August 22, 2026
19.3 C
Bengaluru

How Did Telma Become a 1000+ Cr Brand?

The untold story of Glenmark’s phenomenal success in building a brand, Telma, which has 16 brand extensions and a combined turnover of Rs 1036 crore.

Glenmark’s Telma brand, which contains Telmisartan, has become well-known for treating hypertension and heart failure and preventing heart attacks and strokes.

The HBR case study traces the inception to the rise of Telma, the flagship brand of Glenmark Pharmaceuticals. Telma based on the molecular formulation Telmisartan was introduced by Glenmark in 2003 at a time when the most preferred and market-leading molecule for treating hypertension was Ramipril.

This case not only showcases the brand-building programs undertaken by Glenmark throughout Telma’s life but also traces the marketing efforts that go into creating a new category that would then go on to become the market leader. The case also introduces students to the evolving regulatory framework that has shaped the pharmaceutical marketing practices of generic manufacturers in India since independence.

Glenmark’s ability to quietly build Telma into an INR 1000 crore brand and get featured in the Harvard Business Review in 2015 (HBR) is likely a result of a strategic and well-executed plan.

While the specifics are confidential internal information, we can speculate on some contributing factors:

  • Focus on a Niche Market: Glenmark likely identified a specific, underserved market segment with significant unmet needs. Focusing on this niche allowed them to concentrate resources and build a strong market position without significant direct competition from larger players.
  • Long-Term Vision and Patient Strategy: Building a brand of this size requires significant investment and patience. Glenmark likely adopted a long-term perspective, prioritizing sustained growth and market penetration over rapid, short-term gains. This patient approach allowed for steady organic growth without needing heavy marketing or aggressive expansion.
  • Effective R&D and Product Development: The success is likely rooted in superior product quality and performance. Glenmark’s investment in research and development probably led to innovative and effective products, meeting market demand and enhancing brand reputation.
  • Strong Distribution Network: A well-established distribution network is critical for effectively reaching the target market. Glenmark likely prioritized building strong relationships with distributors and retailers to ensure widespread product availability.
  • Strategic Partnerships: Collaboration with IIM Bangalore suggests a deliberate academic engagement strategy. This partnership likely provided valuable market insights, strategic guidance, and credibility, strengthening the brand’s reputation.
  • Low-Key Marketing: This doesn’t necessarily mean no marketing but a carefully crafted strategy focusing on building trust and brand loyalty through word-of-mouth, relationships with healthcare professionals (HCPs), and targeted campaigns rather than broad, high-profile advertising.
  • Data-Driven Approach: A data-driven approach to understanding consumer preferences and market dynamics allows for a more targeted and efficient use of resources. This would minimize waste and maximize impact.

Do share your thoughts…

A MedicinManAI Market Intelligence Report

Hot this week

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Rajesh Bhogavalli has been appointed as Chief Commercial Officer of ACG Group.

With over 25 years of leadership experience across commercial...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Topics

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Sun Pharma: In the Eye of the Storm of Ophthalmologists

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

Does India Need to Reinvent the Wheel on Junk Foods?

In a written reply in the Lok Sabha in...
spot_img

Related Articles

spot_imgspot_img